KIF6

While Celera can potentially add to Quest's biomarker discovery capabilities and cardiovascular disease testing pipeline, private payors are still not reimbursing for a large share of Celera's products, which may impact how quickly Quest can see a return on its investment.

UCSF will use Celera's KIF6 genetic variant discoveries to develop a test for cardiovascular risk and statin benefit.

Medco wants to know if a gene variant test could predict patient adherence to statin treatment.

Milwaukee-based Aurora Health Care will use Celera's KIF6 test in its heart health programs.

Sometimes genetic tests give inconclusive results and provide little reassurance to patients, the Associated Press reports.

Vox wonders whether gene-editing crops will be viewed similarly as genetically modified organisms of if people will give them a try.

In Science this week: research regulation and reporting requirement reform, and more.

With H3Africa, Charles Rotimi has been working to bolster the representation of African participants and African researchers in genomics, Newsweek reports.